Denali Therapeutics Inc. Common Stock

DNLINASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
18.50 USD
↘ 0.13 (0.67%)🟢LIVE (AS OF 02:01 PM EDT)
🟢Market: OPEN
Open?$18.62
High?$19.10
Low?$18.31
Prev. Close?$18.62
Volume?888.4K
Avg. Volume?1.6M
VWAP?$18.56
Rel. Volume?0.56x
Bid / Ask
Bid?$15.91 × 100
Ask?$18.47 × 100
Spread?$2.56
Midpoint?$17.19
Valuation & Ratios
Market Cap?3.0B
Shares Out?158.7M
Float?128.2M
Float %?87.4%
P/E Ratio?N/A
P/B Ratio?3.19
EPS?-$3.21
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Themes
Biotech - Drug Development›Neuroscience & CNSLongevity & Aging›Age-Related Therapeutics
Employees
507
Market Cap
3.0B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.denalitherapeutics.com
Listed
2017-12-08
Address
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 866-8547
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?9.28Strong
Quick Ratio?9.28Strong
Cash Ratio?3.52Strong
Debt/Equity?0.01Low
ValuationATTRACTIVELY VALUED
Score
83/100
P/E?
N/A▾
P/B?
3.19FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
-4.8CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
-55.0%WEAK▾
ROA?
-40.2%WEAK▾
Cash Flow & Enterprise
FCF?$-419226000
Enterprise Value?$2.6B
Fundamentals ratios updated end of day
MarketsMoversWatchlist